Literature DB >> 1647954

Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects.

K Weisser1, J Schloos, K Lehmann, R Düsing, H Vetter, E Mutschler.   

Abstract

Possible circadian changes in the pharmacokinetics and effect on serum angiotensin-converting enzyme (ACE) activity of the ACE inhibitor enalapril have been studied in 8 healthy subjects after oral ingestion of 10 mg enalapril maleate either at 08.00 h or 20.00 h. The time to peak serum concentration (tmax) of enalapril was increased after administration at 20.00 h compared to 08.00 h (2.4 h versus 1.3 h), whereas other kinetic parameters were not significantly altered. The 24 h-kinetics of the active metabolite enalaprilat did not differ significantly between the two treatments, but the area under the curve (AUC (0-24] and the peak serum concentration (Cmax) were slightly higher after intake at 20.00 h. The relationship between the measured serum enalaprilat level and the degree of inhibition of serum ACE was the same after both treatments. Overall, the evening and morning administration of enalapril did not differ markedly in the pharmacokinetics and the time course of ACE inhibition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647954     DOI: 10.1007/bf00315146

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis.

Authors:  J Lieberman
Journal:  Am J Med       Date:  1975-09       Impact factor: 4.965

2.  Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.

Authors:  R J Francis; A N Brown; L Kler; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

3.  Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers.

Authors:  G Waeber; M Burnier; M Porchet; J Nussberger; B Waeber; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  A diurnal rhythm in plasma renin activity in man.

Authors:  R D Gordon; L K Wolfe; D P Island; G W Liddle
Journal:  J Clin Invest       Date:  1966-10       Impact factor: 14.808

6.  Pharmacokinetics of enalapril in congestive heart failure.

Authors:  K Dickstein
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Circadian rhythm of plasma aldosterone and time dependent alterations of aldosterone regulators.

Authors:  R Takeda; I Miyamori; M Ikeda; H Koshida; Y Takeda; S Yasuhara; T Morise; H Takimoto
Journal:  J Steroid Biochem       Date:  1984-01       Impact factor: 4.292

8.  Enalapril maleate and a lysine analogue (MK-521): disposition in man.

Authors:  E H Ulm; M Hichens; H J Gomez; A E Till; E Hand; T C Vassil; J Biollaz; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

9.  Angiotensin converting enzyme activity in human serum: relationship to enzyme inhibitor in vivo and in vitro.

Authors:  B N Swanson; M Hichens; P Mojaverian; R K Ferguson; P H Vlasses; M Dudash
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-09

10.  Diurnal rhythms of blood pressure, plasma renin activity, angiotensin II and catecholamines in normotensive and hypertensive pregnancies.

Authors:  L J Beilin; J Deacon; C A Michael; R Vandongen; C M Lalor; A E Barden; L Davidson; I Rouse
Journal:  Clin Exp Hypertens B       Date:  1983
View more
  6 in total

1.  Blood pressure response to conventional and low-dose enalapril in chronic renal failure.

Authors:  Thomas Elung-Jensen; Jens Heisterberg; Anne-Lise Kamper; Jesper Sonne; Svend Strandgaard
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients.

Authors:  K Weisser; J Schloos; S Jakob; W Mühlberg; D Platt; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment.

Authors:  M Neubeck; D Fliser; M Pritsch; K Weisser; M Fliser; J Nussberger; E Ritz; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 4.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

5.  Chronopharmacology of enalapril in hypertensive patients.

Authors:  K Sunaga; A Fujimura; T Shiga; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 6.  Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.

Authors:  R J MacFadyen; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.